Related Experiment Videos

Beta-blockers to prevent symptomatic heart failure in patients with stage A and B heart failure

David M Wild1, Marrick Kukin

  • 1Cardiology Clark 3, New York, NY 10025, USA. dwild@chpnet.org

Current Heart Failure Reports
|May 25, 2007
PubMed

Insights

Beta-blockers are not recommended for essential hypertension. However, for asymptomatic left ventricular (LV) dysfunction, beta-blockers improve outcomes and reduce heart failure progression.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Chronic heart failure (CHF) presents a significant economic burden.
  • Physicians often prescribe beta-blockers for asymptomatic left ventricular (LV) dysfunction and hypertension without clear evidence of benefit.
  • Effective therapies limiting CHF progression can reduce costs, morbidity, and mortality.

Purpose of the Study:

  • To review the literature on beta-blocker use in Stage A and B heart failure.
  • To assess the efficacy of beta-blockers in preventing progression to symptomatic heart failure.

Main Methods:

  • Literature review of studies on beta-blocker therapy in early-stage heart failure.
  • Analysis of data regarding beta-blocker use in hypertension, post-myocardial infarction LV dysfunction, and asymptomatic LV dysfunction.

Main Results:

  • Beta-blockers show no benefit in treating essential hypertension.
  • In asymptomatic LV dysfunction post-myocardial infarction, beta-blockers improve mortality and show a trend toward reduced progression to symptomatic heart failure.
  • For asymptomatic chronic LV dysfunction, beta-blockers reduce LV dimensions and improve ejection fraction.

Conclusions:

  • Beta-blockers should not be used as primary treatment for hypertension.
  • All patients with asymptomatic LV dysfunction, irrespective of myocardial infarction history, should receive beta-blocker treatment to prevent symptomatic heart failure progression.

Related Concept Videos

Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...